Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:42:45.850Z.
Calculation as of: 2026-10-06T15:42:45.850Z.
Quote observation: 2026-10-06T15:39:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 65e01e2061821370315a71c231e2ba412a336584d38d2dbcbde0d0d1c3e2cd16
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Mobia Medical, Inc. Common Stock
Market Cap
$310.71M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$297.62M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$290.79M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$289.25M
Price/OCF Ratio
N/A
TTM Avg
4132.33
3Y Avg
4132.33
5Y Avg
4132.33
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mobia Medical, Inc. Common Stock (MOBI) | $310.71M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $303.53M | N/A | N/A | N/A | N/A |
| Avita Medical Inc. (RCEL)vs › | $318.73M | N/A | N/A | N/A | N/A |
| CapsoVision, Inc. (CV)vs › | $319.27M | N/A | N/A | N/A | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $321.20M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $297.62M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $290.97M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $290.79M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $289.25M | N/A | 4132.33 | 4132.33 | 4132.33 |
| ClearPoint Neuro, Inc. (CLPT)vs › | $332.28M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
